DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments

Information source: Chiron Corporation
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Lymphoma, Non-Hodgkin

Intervention: Recombinant Human Interleukin-2 and Rituximab (Drug)

Phase: Phase 2/Phase 3

Status: Completed

Sponsored by: Chiron Corporation

Summary

The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have previously failed Rituxan treatments.

Clinical Details

Study design: Primary Purpose: Treatment

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Diagnosis and disease status:

- Subjects with CD20+, B-cell, Non-Hodgkin's lymphoma of low-grade or follicular

histology with measurable relapsed or unresponsive disease after prior therapy; mantle cell and chronic lymphocytic leukemia subtypes are excluded.

- Subjects who previously received a single-agent course of rituximab and showed no

tumor response, or had a response lasting < 6 months. The previously administered rituximab must have included at least 75% of the standard 4-week regimen (4 x 375 mg/m2). A record of the previous rituximab treatment and response must be available as a source document at the site. Exclusion:

- Subjects who showed no tumor response or a response lasting <6 months to treatment

with Rituximab in combination with Chemotherapy or another therapeutic modality (radiation or radioimmunoconjugates).

- HIV positive.

- Symptomatic thyroid disease requiring medical intervention other than replacement

treatment for hypothyroidism.

- Clinically significant cardiac, pulmonary, and /or hepatic dysfunction (if subject

has history of congestive heart failure or myocardial infarction, must have been stable for at least 6 months, and have no current symptoms

- If cardiac ejection fraction has been measured, it must be greater than 50%.

Locations and Contacts

University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, United States

Comprehensive Blood and Cancer Center, Bakersfield, California 93309, United States

California Oncology of the Central Valley, Fresno, California 93710, United States

Virginia K. Crosson Cancer Center, Fullerton, California 92835, United States

Pacific Shores Medical Group, Glendale, California 91204, United States

Wilshire Oncology Medical Group, Glendora, California 91741, United States

California Cancer Care Inc., Greenbrae, California 94904, United States

Pacific Shores Medical Group, Huntington Beach, California 92648, United States

Santa Barbara Hematology Oncology Medical Group, Lompoc, California 93438, United States

Pacific Shores Medical Group, Long Beach, California 90813, United States

Pacific Shores Medical Group, Los Alamitos, California 90720, United States

UCLS Medical Center, Los Angeles, California 90095, United States

Facey Medical Foundation, Mission Hills, California 91345, United States

North Valley Hematology-Oncology Medical Group, Mission Hills, California 91345, United States

Hoag Cancer Center, Newport Beach, California 92658, United States

North Valley Hematology/Oncology Medical Group, Northridge, California 91328, United States

Ventura County Hematology-Oncology Specialists, Oxnard, California 93030, United States

UCLA Medical Group/Pasadena Oncology, Pasadena, California 91105, United States

Wilshire Oncology Medical Group, Pasadena, California 91105, United States

Wilshire Oncology Medical Group, Pomona, California 91767, United States

Southwest Cancer Care, Poway, California 92064, United States

Wilshire Oncology Medical Group, Rancho Cucamonga, California 91730, United States

Cancer Care Associates Meidcal Group, Inc., Redondo Beach, California 90277, United States

UC Davis Cancer Center, Sacramento, California 95817, United States

Sansum Santa Barbara Foundation Medical Clinic, Santa Barbara, California 93105, United States

Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California 93105, United States

Santa Barbara Hematology Oncology Medical Group, Santa Maria, California 93454, United States

John Wayne Cancer Institute, Santa Monica, California 90404, United States

Santa Barbara Hematology Oncology Medical Group, Solvang, California 93463, United States

Cancer Care Associates Medical Group, Inc., Torrance, California 90505, United States

UCLA/Santa Clarita Valley Cancer Center, Valencia, California 91355, United States

Ventura County Hematology-Oncology Specialists, Ventura, California 93003, United States

San Diego Cancer Center Medical Group, Vista, California 92083, United States

Wilshire Oncology Medical Group, West Covina, California 91790, United States

Whittingham Cancer Center, Norwalk, Connecticut 06856, United States

Division of Hematology/Oncology, University of Miami, School of Medicine, Miami, Florida 33136, United States

Cancer Research Center of Hawaii, Honolulu, Hawaii 96813, United States

Northwestern University Medical School, Chicago, Illinois 60611, United States

Oncology Specialists,S.C., Park Ridge, Illinois 60068, United States

Cancer Care Center, Bloomington, Indiana 47403, United States

Indiana Oncology and Hematology Consultants, Indianapolis, Indiana 46202, United States

University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, United States

Consultants in Blood Disorders and Cancer, Louisville, Kentucky 40207, United States

Hematology and Oncology Specialists, LLC, New Orleans, Louisiana 70115, United States

Louisiana State University Health Sciences Center and VA, Shreveport, Louisiana 71130, United States

Maine Center for Cancer Medicine & Blood Disorders, Scarborough, Maine 04074, United States

Kansas City Oncology and Hematology Group, Kansas City, Missouri 64111, United States

Benefis Healthcare, Great Falls, Montana 59405, United States

Comprehensive Cancer Centers of Nevada, Henderson, Nevada 89052, United States

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada 89109, United States

Northern New Jersey Cancer Associates, Hackensack, New Jersey 07601, United States

Erie County Medical Center, Buffalo, New York 14215, United States

Advanced Oncology Associates, New Rochelle, New York 10801, United States

Mount Sinai School of Medicine, New York, New York 10029, United States

Weill Medical College of Cornell University/New York Presbyterian Hospital, New York, New York 10021, United States

East Carolina University School of Medicine, Department of Medicine, Division of Hematology/Oncology, Greenville, North Carolina 27858-4354, United States

Gabrail Cancer Center, Canton, Ohio 44718, United States

The Cleveland Clinic Foundation, Cleveland, Ohio 44195, United States

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio 43210, United States

Hematology Oncology Consultants, Inc., Columbus, Ohio 43235, United States

Oregon Health & Science University, Portland, Oregon 97201, United States

Cancer Centers of the Carolinas, Greenville, South Carolina 29605, United States

Germantown Cancer Foundation, Germantown, Tennessee 38138, United States

Fletcher Allen Health Care, Burlington, Vermont 05401, United States

Virginia Cancer Institute, Richmond, Virginia 23230, United States

Additional Information


Last updated: February 2, 2006

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017